Latest News and Press Releases
Want to stay updated on the latest news?
-
August 20, 2018Announcement no. 15 In accordance with the company's guidelines relating to incentive remuneration and the authorization in Section 18 of the Articles of Association, the Board of...
-
August 16, 2018Announcement no. 14 BioPorto submits application to the FDA for clinical use of The NGAL Test™ in the US BioPorto completed the clinical studies for The NGAL Test™ in...
-
July 18, 2018 Announcement no. 13 BioPorto A/S (“BioPorto”) announces today that the company has submitted an application to the US Food and Drug Administration, (“FDA”), for regulatory clearance...
-
June 27, 2018 Announcement no. 12 BioPorto A/S (“BioPorto”) has successfully completed clinical studies for The NGAL Test™ in collaboration with leading US hospitals. The data...
-
June 15, 2018Announcement no. 11 In accordance with the company's guidelines relating to incentive remuneration and the authorization in Section 18 of the Articles of Association, the Board of...
-
May 3, 2018Announcement no. 10 Important milestones in global roll-out of The NGAL Test™ secured in first quarter 2018 In the first quarter of 2018, BioPorto secured...
-
April 18, 2018Announcement no. 9 Ole Larsen, Executive Vice President & CFO of Bavarian Nordic, will as of June 1, 2018, join BioPorto as the new Chief Financial Officer. In 2008, Ole Larsen...
-
April 13, 2018Announcement no. 8 BioPorto A/S held its Annual General Meeting today where the shareholders approved the report on the Company’s activities and adopted the 2017 Annual Report. In...
-
April 3, 2018Announcement no. 7 BioPorto receives intention to grant for a divisional NGAL cutoff patent in Europe The European Patent Office has published intention to grant BioPorto’s patent no....
-
21. marts 2018 Meddelelses nummer: 6 Indkaldelse til ordinær generalforsamling Bestyrelsen indkalder herved til ordinær generalforsamling i BioPorto A/S: Den 13. april 2018, kl. 15.00 På...